X4 Pharmaceuticals (XFOR) Income towards Parent Company (2018 - 2025)
Historic Income towards Parent Company for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to -$29.8 million.
- X4 Pharmaceuticals' Income towards Parent Company rose 1875.14% to -$29.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$95.1 million, marking a year-over-year decrease of 46742.65%. This contributed to the annual value of -$37.4 million for FY2024, which is 6298.2% up from last year.
- X4 Pharmaceuticals' Income towards Parent Company amounted to -$29.8 million in Q3 2025, which was up 1875.14% from -$25.7 million recorded in Q2 2025.
- X4 Pharmaceuticals' Income towards Parent Company's 5-year high stood at $90.8 million during Q2 2024, with a 5-year trough of -$55.7 million in Q2 2023.
- In the last 5 years, X4 Pharmaceuticals' Income towards Parent Company had a median value of -$22.0 million in 2022 and averaged -$19.8 million.
- Over the last 5 years, X4 Pharmaceuticals' Income towards Parent Company had its largest YoY gain of 26304.03% in 2024, and its largest YoY loss of 149201.74% in 2024.
- Quarter analysis of 5 years shows X4 Pharmaceuticals' Income towards Parent Company stood at -$30.2 million in 2021, then rose by 3.65% to -$29.1 million in 2022, then surged by 34.27% to -$19.1 million in 2023, then crashed by 108.16% to -$39.8 million in 2024, then increased by 25.13% to -$29.8 million in 2025.
- Its last three reported values are -$29.8 million in Q3 2025, -$25.7 million for Q2 2025, and $282000.0 during Q1 2025.